FORMULATION AND CHARACTERIZATION OF CHRONO MODULATED COLON TARGAED DRUG DELIVERY OF VEDOLIZUMAB DRUG

Abstract

Chrono-modulated drug delivery systems hold the promise of optimizing treatment regimens for chronic inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, through Vedolizumab. These conditions exhibit diurnal variations in disease activity, making the synchronization of drug release with peak inflammation periods paramount for enhanced therapeutic efficacy. In this study, we explore the formulation, development, and characterization of chrono-modulated delivery systems designed to align Vedolizumab release with the colon, reducing systemic exposure and associated side effects. Patient adherence is improved through tailored treatment schedules that harmonize with daily routines and circadian rhythms. As research progresses, the potential for personalized Vedolizumab therapy emerges, wherein drug release profiles are adapted to individual chronobiological rhythms. Furthermore, the reduced frequency of drug administration lightens the treatment burden on patients and healthcare providers. This research not only transforms the treatment landscape for inflammatory bowel diseases but also offers broader implications for drug delivery and chronotherapy in various therapeutic areas.